These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37363972)

  • 1. Updates on the Treatment of Tenosynovial Giant Cell Tumor.
    Chan AS; Katiyar V; Dy P; Singh V
    Hematol Oncol Stem Cell Ther; 2023 May; 16(4):307-315. PubMed ID: 37363972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment updates on tenosynovial giant cell tumor.
    Palmerini E; Staals EL
    Curr Opin Oncol; 2022 Jul; 34(4):322-327. PubMed ID: 35837703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development.
    Benner B; Good L; Quiroga D; Schultz TE; Kassem M; Carson WE; Cherian MA; Sardesai S; Wesolowski R
    Drug Des Devel Ther; 2020; 14():1693-1704. PubMed ID: 32440095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors.
    Baldi GG; Gronchi A; Stacchiotti S
    Expert Rev Clin Pharmacol; 2020 Jun; 13(6):571-576. PubMed ID: 32478598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The MOTION study: a randomized, phase III study of vimseltinib for the treatment of tenosynovial giant cell tumor.
    Tap WD; Sharma MG; Vallee M; Smith BD; Sherman ML; Ruiz-Soto R; de Sande MV; Randall RL; Bernthal NM; Gelderblom H
    Future Oncol; 2024 Mar; 20(10):593-601. PubMed ID: 37593881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy.
    Palmerini E; Longhi A; Donati DM; Staals EL
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):441-445. PubMed ID: 32297819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pexidartinib (TURALIO™): The First FDA-Indicated Systemic Treatment for Tenosynovial Giant Cell Tumor.
    Monestime S; Lazaridis D
    Drugs R D; 2020 Sep; 20(3):189-195. PubMed ID: 32617868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis.
    Brahmi M; Vinceneux A; Cassier PA
    Curr Treat Options Oncol; 2016 Feb; 17(2):10. PubMed ID: 26820289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT).
    Caldwell TM; Ahn YM; Bulfer SL; Leary CB; Hood MM; Lu WP; Vogeti L; Vogeti S; Kaufman MD; Wise SC; Le Bourdonnec B; Smith BD; Flynn DL
    Bioorg Med Chem Lett; 2022 Oct; 74():128928. PubMed ID: 35961460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy.
    Nakayama R; Jagannathan JP; Ramaiya N; Ferrone ML; Raut CP; Ready JE; Hornick JL; Wagner AJ
    BMC Cancer; 2018 Dec; 18(1):1296. PubMed ID: 30594158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib.
    Gelderblom H; Razak AA; Taylor MH; Bauer TM; Wilky B; Martin-Broto J; Gonzalez AF; Rutkowski P; Szostakowski B; Alcindor T; Saleh R; Genta S; Stacchiotti S; van de Sande M; Wagner AJ; Bernthal N; Davis LE; Vuky J; Tait C; Matin B; Narasimhan S; Sharma MG; Ruiz-Soto R; Sherman ML; Tap WD
    Clin Cancer Res; 2024 Sep; 30(18):3996-4004. PubMed ID: 38995311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA.
    Dharmani C; Fofah O; Wang E; Salas M; Wooddell M; Tu N; Tse J; Near A; Tinoco G
    Future Oncol; 2024; 20(16):1079-1097. PubMed ID: 38380590
    [No Abstract]   [Full Text] [Related]  

  • 13. Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages.
    Smith BD; Kaufman MD; Wise SC; Ahn YM; Caldwell TM; Leary CB; Lu WP; Tan G; Vogeti L; Vogeti S; Wilky BA; Davis LE; Sharma M; Ruiz-Soto R; Flynn DL
    Mol Cancer Ther; 2021 Nov; 20(11):2098-2109. PubMed ID: 34433663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study.
    Bernthal NM; Spierenburg G; Healey JH; Palmerini E; Bauer S; ; Gelderblom H; Staals EL; Lopez-Bastida J; Fronk EM; Ye X; Laeis P; van de Sande MAJ
    Orphanet J Rare Dis; 2021 Apr; 16(1):191. PubMed ID: 33926503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on Tenosynovial Giant Cell Tumor, an Inflammatory Arthritis With Neoplastic Features.
    Robert M; Farese H; Miossec P
    Front Immunol; 2022; 13():820046. PubMed ID: 35265077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extensile Anterior and Posterior Knee Exposure for Complete Synovectomy of Diffuse Tenosynovial Giant Cell Tumor (Pigmented Villonodular Synovitis).
    Lingamfelter M; Novaczyk ZB; Cheng EY
    JBJS Essent Surg Tech; 2022; 12(2):. PubMed ID: 36741035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects of Treating Tenosynovial Giant Cell Tumor through Pexidartinib: A Review.
    Alsayadi YMMA; Chawla PA
    Anticancer Agents Med Chem; 2021; 21(12):1510-1519. PubMed ID: 33143617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of colony-stimulating factor 1 in the neoplastic process of tenosynovial giant cell tumor.
    Tap WD; Healey JH
    Tumour Biol; 2022; 44(1):239-248. PubMed ID: 36502356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor.
    Gelderblom H; de Sande MV
    Future Oncol; 2020 Oct; 16(29):2345-2356. PubMed ID: 32700568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffuse-type tenosynovial giant cell tumour: Current treatment concepts and future perspectives.
    Staals EL; Ferrari S; Donati DM; Palmerini E
    Eur J Cancer; 2016 Aug; 63():34-40. PubMed ID: 27267143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.